Orchid vs Manus AI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Wilmington DE YC W23 AI clinical notes EHR for mental health therapists; $728K total ($500K YC seed Oct 2023) with HIPAA-compliant AI notes and EHR integration competing with SimplePractice for independent therapist documentation.
About
Orchid is a Wilmington, Delaware-based AI-powered EHR platform for mental health professionals — backed by Y Combinator (W23) with $728,000 in total funding including a $500,000 seed in October 2023 from Y Combinator — providing independent mental health clinicians (therapists, psychologists, counselors) with HIPAA-compliant AI clinical notes that integrate with any existing EHR, automating note-taking to free time for patient care. Launched Orchid AI in July 2024, with e-prescribing planned for 2025, Orchid streamlines the administrative workflows and clinical documentation burden that forces mental health professionals to spend 2-3 hours daily on paperwork that competes with patient care time. Founded in 2020, targeting the solo and small group independent mental health practice market.
General-purpose autonomous AI agent. $125M+ revenue run rate. Acquired by Meta for $2B+ (Dec 2025). Founded 2022, China/Singapore. MIT Innovators Under 35.
About
Manus AI is a general-purpose autonomous AI agent developed by Butterfly Effect Pte Ltd, founded in 2022 by Yichao "Peak" Ji and Xiao Hong. Relocated from China to Singapore (mid-2025). Launched March 6, 2025, autonomously handling complex tasks like market research, coding, data analysis, and content creation without human intervention.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.